Stephen J. Noga

Stephen J. Noga is a highly experienced medical professional currently serving as the Medical Lead for the Multiple Myeloma Franchise and Cell Therapy at Takeda Oncology.1 He has been in this role since June 2020 and is based in the Greater Boston Area.1

Career at Takeda Oncology

Dr. Noga has held several leadership positions within Takeda Oncology:

• Vice President, US Medical Affairs - Oncology (March 2018 - Present): In this role, he oversees Medical Affairs for US pharmaceuticals, including NINLARO, ALUNBRIG, ICLUSIG, and VELCADE.1

• Head, U.S. Oncology Medical Affairs (January 2017 - Present): He leads the development and implementation of U.S. medical affairs strategy for both approved and pipeline oncology molecules.1

• Senior Medical Director, Global Medical Oncology Affairs (June 2015 - Present): He served as the US Medical Lead for ixazomib and Velcade.1

Previous Experience

Before joining Takeda Oncology, Dr. Noga had an extensive career in medical oncology:

• Medical Director at MedStar Harbor Hospital's Cancer Center (December 2014 - June 2015)
• Medical Director of the Oncology Service Line at MedStar Health (October 2010 - June 2015)
• Director of Medical Oncology/Hematology at Sinai Hospital (August 2001 - September 2010)
• Associate Professor of Oncology & Pathology at The Johns Hopkins Hospital (1983 - 2001)1

Education

Dr. Noga has a strong educational background:

• MD from The Johns Hopkins University School of Medicine (1983 - 1987)
• Ph.D. in Experimental Pathology - Hematopathology from the University of Florida College of Medicine (1977 - 1983)
• BS in Medical Technology from the University of Florida (1972 - 1976)1

Throughout his career, Dr. Noga has demonstrated expertise in areas such as bone marrow transplantation, hematologic malignancies, and cellular engineering.1